Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease

Next Previous
Trial Profile

A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Fosbretabulin (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions

Most Recent Events

  • 06 Aug 2019 Status changed from active, no longer recruiting to discontinued.
  • 04 Jun 2019 Results (n=17) presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
  • 03 Apr 2019 Results assessing safety and tolerability of Fosbretabulin in combination with everolimus in neuroendocrine tumors presented at the 110th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top